S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
Are blue chip stocks a good investment?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Power Play: GE's game-changing technology for EVs and grids
Home sales hit a 13-year low... what now?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Stock market today: World shares mixed after Wall St ends its best month of '23 with big gains
Salesforce.com completes a reversal: new all-time high in sight
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
A 15% gain in store for Five Below after rosy holiday outlook
Elon Musk Gives Profanity-Laden Tirade During DealBook Interview: "Go F--- Yourself'
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
Are blue chip stocks a good investment?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Power Play: GE's game-changing technology for EVs and grids
Home sales hit a 13-year low... what now?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Stock market today: World shares mixed after Wall St ends its best month of '23 with big gains
Salesforce.com completes a reversal: new all-time high in sight
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
A 15% gain in store for Five Below after rosy holiday outlook
Elon Musk Gives Profanity-Laden Tirade During DealBook Interview: "Go F--- Yourself'
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
Are blue chip stocks a good investment?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Power Play: GE's game-changing technology for EVs and grids
Home sales hit a 13-year low... what now?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Stock market today: World shares mixed after Wall St ends its best month of '23 with big gains
Salesforce.com completes a reversal: new all-time high in sight
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
A 15% gain in store for Five Below after rosy holiday outlook
Elon Musk Gives Profanity-Laden Tirade During DealBook Interview: "Go F--- Yourself'
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
Are blue chip stocks a good investment?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Power Play: GE's game-changing technology for EVs and grids
Home sales hit a 13-year low... what now?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Stock market today: World shares mixed after Wall St ends its best month of '23 with big gains
Salesforce.com completes a reversal: new all-time high in sight
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
A 15% gain in store for Five Below after rosy holiday outlook
Elon Musk Gives Profanity-Laden Tirade During DealBook Interview: "Go F--- Yourself'

Alimera Sciences Stock Price, News & Analysis (NASDAQ:ALIM)

$3.08
-0.06 (-1.91%)
(As of 11/30/2023 ET)
Compare
Today's Range
$2.95
$3.28
50-Day Range
$2.63
$3.50
52-Week Range
$1.30
$3.90
Volume
66,385 shs
Average Volume
29,789 shs
Market Capitalization
$161.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.50

Alimera Sciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
110.7% Upside
$6.50 Price Target
Short Interest
Bearish
0.30% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.94mentions of Alimera Sciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$1.96 M Bought Last Quarter
Proj. Earnings Growth
-77.78%
From $0.54 to $0.12 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

545th out of 948 stocks

Pharmaceutical Preparations Industry

265th out of 444 stocks


ALIM stock logo

About Alimera Sciences Stock (NASDAQ:ALIM)

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals. It operates through United States, internationally, and Operating Cost segments. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, clinics, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

ALIM Stock Price History

ALIM Stock News Headlines

StockNews.com Begins Coverage on Alimera Sciences (NASDAQ:ALIM)
Alimera Appoints Maggie A. Pax to Its Board of Directors
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Alimera Sciences Reports Third Quarter 2023 Results
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Alimera Sciences Q3 2023 Earnings Preview
Alimera Sciences, Inc.'s (NASDAQ:ALIM) Profit Outlook
The Latest Analyst Ratings for Alimera Sciences
Q2 2023 Alimera Sciences Inc Earnings Call
See More Headlines
Receive ALIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alimera Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/26/2023
Today
12/01/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/29/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALIM
Employees
150
Year Founded
2003

Price Target and Rating

Average Stock Price Target
$6.50
High Stock Price Target
$8.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+110.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-18,110,000.00
Pretax Margin
-29.29%

Debt

Sales & Book Value

Annual Sales
$54.13 million
Book Value
$0.93 per share

Miscellaneous

Free Float
35,958,000
Market Cap
$161.72 million
Optionable
Optionable
Beta
1.43

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report














ALIM Stock Analysis - Frequently Asked Questions

Should I buy or sell Alimera Sciences stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALIM shares.
View ALIM analyst ratings
or view top-rated stocks.

What is Alimera Sciences' stock price target for 2024?

2 equities research analysts have issued 12 month target prices for Alimera Sciences' stock. Their ALIM share price targets range from $5.00 to $8.00. On average, they expect the company's stock price to reach $6.50 in the next year. This suggests a possible upside of 110.7% from the stock's current price.
View analysts price targets for ALIM
or view top-rated stocks among Wall Street analysts.

How have ALIM shares performed in 2023?

Alimera Sciences' stock was trading at $2.71 at the beginning of 2023. Since then, ALIM stock has increased by 13.8% and is now trading at $3.0850.
View the best growth stocks for 2023 here
.

When is Alimera Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our ALIM earnings forecast
.

How were Alimera Sciences' earnings last quarter?

Alimera Sciences, Inc. (NASDAQ:ALIM) released its quarterly earnings data on Thursday, October, 26th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.35. The biopharmaceutical company earned $23.36 million during the quarter, compared to the consensus estimate of $24.40 million.

When did Alimera Sciences' stock split?

Alimera Sciences shares reverse split on Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 14th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is Rick Eiswirth's approval rating as Alimera Sciences' CEO?

2 employees have rated Alimera Sciences Chief Executive Officer Rick Eiswirth on Glassdoor.com. Rick Eiswirth has an approval rating of 100% among the company's employees. This puts Rick Eiswirth in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alimera Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN), AngloGold Ashanti (AU), SSR Mining (SSRM), ADMA Biologics (ADMA) and Cellectar Biosciences (CLRB).

Who are Alimera Sciences' major shareholders?

Alimera Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Stonepine Capital Management LLC (7.60%), AIGH Capital Management LLC (4.53%), Worth Venture Partners LLC (1.13%), Tower Research Capital LLC TRC (0.02%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Adam Morgan, Alto Investors Lp Palo, Caligan Partners Lp, James R Largent, John Philip Jones, Philip Ashman, Richard S Eiswirth Jr and Stanley Morgan.
View institutional ownership trends
.

How do I buy shares of Alimera Sciences?

Shares of ALIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ALIM) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -